EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Bioequivalence Study of Two Empagliflozin Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions

Yuyan Lei, Yuan Liu, Lichen Gao, Xueqiong Peng, Lulu Chen, Chao Li, Weiming Chen, Junmei Xu, Dongsheng Ouyang, Xiaohui Li

Clinical Pharmacology in Drug Development · 2025

DOI: 10.1002/cpdd.1530 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Yuyan Lei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Study Laboratory, The Second Nanning People's Hospital, Nanning, China. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Fasting, Food-Drug Interactions, Glucosides. Die Arbeit nennt 22 Literaturangaben. Gefördert von: International Scientific and Technological Innovation Cooperation Base for Bioanalysis of Complex Matrix Samples, Nature Science Foundation, Hunan Science and Technology Youth Talent Support Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Empagliflozin is a highly selective sodium‐glucose cotransporter 2 inhibitor and an effective medication for treating diabetes. This study aimed to assess the pharmacokinetics and bioequivalence of two 10‐mg empagliflozin tablets in healthy Chinese subjects and examine food's effect on absorption. The research was conducted as a single‐center, randomized, open‐label, single‐dose, 2‐way crossover study involving 47 subjects (fasting: n = 23, fed: n = 24). Subjects received either the test or reference drug and switched to the alternative after a 7‐day washout period. Blood samples were collected before administration and up to 48 hours after dosing, analyzed using validated liquid chromatography‐tandem mass spectrometry techniques to determine empagliflozin levels. In both studies, all 23 subjects completed the study phases under fasting and fed conditions. In both scenarios, when comparing the test and reference formulations, the 90% confidence intervals for the geometric mean ratios of maximum plasma concentration, area under the concentration‐time curve from time 0 to the last measurable concentration, and area under the concentration‐time curve from time 0 to infinity fell within the bioequivalence threshold of 80%‐125%, confirming their acceptability. The study found that a high‐fat meal slightly reduced drug exposure and slightly accelerated absorption. No serious adverse events were observed. This research confirmed the pharmacokinetic similarity of the 2 empagliflozin formulations and demonstrated their good tolerance under fasting and fed conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsFastingFood-Drug InteractionsGlucosidesSodium-Glucose Transporter 2 InhibitorsAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralArea Under CurveCross-Over StudiesHealthy VolunteersTabletsTandem Mass SpectrometryTherapeutic EquivalencyEast Asian People

Stichwörter der Autor:innen

LC‐MS/MSbioequivalenceempagliflozinhealthy subjectpharmacokinetics

Substanzen

Benzhydryl CompoundsempagliflozinGlucosidesSodium-Glucose Transporter 2 InhibitorsTablets

Autor:innen und Institutionen

  • Phase I Clinical Study Laboratory, The Second Nanning People's Hospital, Nanning, China.
  • Department of Pharmacology, Xiangya School of Pharmaceutical Science, Central South University, Changsha, China.
  • Department of Anesthesiology, The Second Xiangya Hospital of Central South University, Changsha, China.
  • Department of Pharmacy, Cancer Institute, PhaseIClinical Study Centre, Changsha Central Hospital Affiliated to University of South China, Changsha, China.
  • Institute of Pharmacy and Pharmacology, University of South China, Hengyang, China.
  • Changsha Duxact Biotech Co., Ltd, Changsha, China.

Förderung

  • International Scientific and Technological Innovation Cooperation Base for Bioanalysis of Complex Matrix Samples
  • Nature Science Foundation
  • Hunan Science and Technology Youth Talent Support Program
  • Science and Technology Innovation Program of Hunan Province

Zitieren

APA

Lei, Y., Liu, Y., Gao, L., Peng, X., Chen, L., Li, C., Chen, W., Xu, J., Ouyang, D., & Li, X. (2025). Bioequivalence Study of Two Empagliflozin Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1530

Vancouver

Lei Y, Liu Y, Gao L, Peng X, Chen L, Li C, et al. Bioequivalence Study of Two Empagliflozin Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1530

BibTeX
@article{Lei2025,
  author = {Lei, Yuyan and Liu, Yuan and Gao, Lichen and Peng, Xueqiong and Chen, Lulu and Li, Chao and Chen, Weiming and Xu, Junmei and Ouyang, Dongsheng and Li, Xiaohui},
  title = {Bioequivalence Study of Two Empagliflozin Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  doi = {10.1002/cpdd.1530}
}
Kostenlos starten →